Unicycive Therapeutics, Inc. (UNCY) — Analyst outlook / Analyst consensus target is. Based on 6 analyst ratings, the consensus is bullish — 6 Buy.
Analysts estimate Earnings Per Share (EPS) of $-5.14 and revenue of $0.01B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-0.06 vs est $-5.14 (beat +98.9%). 2025: actual $-1.67 vs est $-1.45 (missed -15.5%). Analyst accuracy: 0%.
UNCY Analyst Ratings
Buy
Based on 6 analysts giving stock ratings to Unicycive Therapeutics, Inc. in the past 3 months
EPS Estimates — UNCY
0%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual –$0.06
vs Est –$5.14
▲ 9,002.4% off
2025
Actual –$1.67
vs Est –$1.45
▼ 13.4% off
Profitability Outlook
Company has been making losses in all recent fiscal years. Analysts expect losses to continue near-term.
Revenue Estimates — UNCY
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
